Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 30,500 | |||
5 mg | 在庫あり | ¥ 75,500 | |||
10 mg | 在庫あり | ¥ 123,500 | |||
25 mg | 在庫あり | ¥ 199,500 | |||
50 mg | 在庫あり | ¥ 271,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 78,000 |
説明 | CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3). |
In vitro | CFT7455 enables potent cell growth inhibition in both previously untreated NCIH929 multiple myeloma cell lines with an IC50 of 0.071 nM and NCIH929 cells made resistant to both lenalidomide and pomalidomide with an IC50 of 2.3 nM. CFT7455 promotes the degradation of >75% of steady state IKZF1 in multiple myeloma cells within 1.5 hours at 0.3 nM[1]. |
In vivo | In mouse xenograft tumor models, CFT7455 (3 μg/kg-100 μg/kg) led to durable tumor regression and demonstrates dose-dependent efficacy[1]. |
別名 | Cemsidomide |
分子量 | 469.53 |
分子式 | C28H27N3O4 |
CAS No. | 2504235-67-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20 mg/mL (42.60 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CFT7455 2504235-67-8 PROTAC Ligand for E3 Ligase cereblon CFT 7455 Ligands for E3 Ligase anti-cancer agent inhibit Inhibitor orally active CFT-7455 E3 ligase-recruiting Moiety IKZF3 degrader IKZF1 Cemsidomide inhibitor